Cost-effectiveness Analysis of Toripalimab for Metastatic or Recurrent Triple-Negative Breast Cancer
Frontiers in Oncology（2024）
Key words
cost-effectiveness analysis,toripalimab,PD-L1 positive,triple negative breast cancer,immunotherapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined